Umi1 schreef op 29 maart 2025 23:39:
[...]
Vandaag toch niet 2 studies uitgekomen omtrent dit topic zeker?
"Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1."
www.novonordisk.com/content/nncorp/gl...---------------
Ozempic® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes and peripheral artery disease (PAD) in the phase 3 STRIDE trial1.
Approximately 230 million people globally have PAD, a severe form of atherosclerotic cardiovascular disease3, and nearly one in three people with PAD have type 2 diabetes4.
www.novonordisk.com/content/nncorp/gl..." SAEs led to the death of 3 (1%) and 8 (2%) participants in the semaglutide and placebo arms, respectively; however, no SAEs leading to death were treatment-related"
-> Duidelijk verschil toch in overlevingskansen lijkt me? & dat op een beperkte duur studie (52w) Mij lijkt me de gezondheidswinst op LT nog groter...
----------------
ivm dividendvraag; google zegt dat 28/03 ex-div date was. Dus dividend is normaal reeds van de koers af.